NEOGENOMICS INC (NEO) Stock
4 members of Congress disclosed 6 trades in NEO since 2020: 4 purchases and 2 sales, most recently Gilbert Cisneros (purchase, Aug 7, 2026). 3 of the hedge funds AlphaScala tracks reported NEO in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $44.93M.
Which members of Congress traded NEOGENOMICS INC (NEO)?
Most recent: Gilbert Cisneros (purchase, Aug 7, 2026); records start Mar 2, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-08-07 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-05-07 | purchase | $1k – $15k |
| Dwight Evans D-PA · House | 2022-03-30 | sale | $1k – $15k |
| Deborah Ross D-NC · House | 2021-12-30 | purchase | $15k – $50k |
| Bob Gibbs R-OH · House | 2021-11-09 | sale | $1k – $15k |
| Dwight Evans D-PA · House | 2020-03-02 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all NEO political trades →Which hedge funds own NEO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.08M | $44.93M | +39% |
| D.E. Shaw David Shaw | 2.19M | $32.02M | -47% |
| Hussman Investment Trust John Hussman | 105K | $1.93M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are NEOGENOMICS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 4, 26 | Aunan Greg D | Chief Accounting Officer | SELL | 20.0K | $321K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →NEO price chart
Powered by TradingViewWhat does NEOGENOMICS INC do?
NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services. It offers one of the most comprehensive menus of oncology-focused tests worldwide, including next-generation sequencing (NGS), comprehensive genomic profiling, and advanced assays like RaDaR ST for molecular residual disease (MRD) detection in solid tumors and PanTracer Pro for integrated diagnostics in advanced-stage cancers. The company provides clinical cancer testing, professional interpretation by pathologists and molecular experts, clinical trials support, research services, validation laboratory services, and oncology data solutions to pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, and managed care organizations across the United States and Europe. NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in multiple U.S. locations and the United Kingdom, with its Pharma Services Division supporting drug development for pharmaceutical clients. Founded in 1998 and headquartered in Fort Myers, Florida, NeoGenomics plays a key role in precision oncology by enabling personalized cancer diagnosis and treatment.